SG11202005863TA - Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof - Google Patents

Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof

Info

Publication number
SG11202005863TA
SG11202005863TA SG11202005863TA SG11202005863TA SG11202005863TA SG 11202005863T A SG11202005863T A SG 11202005863TA SG 11202005863T A SG11202005863T A SG 11202005863TA SG 11202005863T A SG11202005863T A SG 11202005863TA SG 11202005863T A SG11202005863T A SG 11202005863TA
Authority
SG
Singapore
Prior art keywords
probiotics
ige
polypeptide
composition
binding affinity
Prior art date
Application number
SG11202005863TA
Inventor
Myoung Ho Jang
Young Chul Sung
Zungyoon Yang
Original Assignee
Gi Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gi Innovation Inc filed Critical Gi Innovation Inc
Publication of SG11202005863TA publication Critical patent/SG11202005863TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11202005863TA 2018-01-12 2019-01-14 Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof SG11202005863TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180004421 2018-01-12
PCT/KR2019/000524 WO2019139434A1 (en) 2018-01-12 2019-01-14 Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof

Publications (1)

Publication Number Publication Date
SG11202005863TA true SG11202005863TA (en) 2020-07-29

Family

ID=67218660

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005863TA SG11202005863TA (en) 2018-01-12 2019-01-14 Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof

Country Status (16)

Country Link
US (1) US20220347236A1 (en)
EP (1) EP3738599B1 (en)
JP (1) JP7041272B2 (en)
KR (1) KR102038679B1 (en)
CN (1) CN111587118B (en)
AU (1) AU2019206205A1 (en)
BR (1) BR112020013818A2 (en)
CA (1) CA3086224A1 (en)
CL (1) CL2020001800A1 (en)
IL (1) IL275593B (en)
MX (1) MX2020007032A (en)
PE (1) PE20210108A1 (en)
PH (1) PH12020551069A1 (en)
SG (1) SG11202005863TA (en)
TW (1) TWI737955B (en)
WO (1) WO2019139434A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022000246A2 (en) * 2019-07-08 2022-02-22 Gi Innovation Inc A high sialic acid polypeptide dimer comprising the extracellular domain of the ige fc receptor alpha subunit and a pharmaceutical composition comprising the same
EP4183803A4 (en) * 2020-07-17 2024-04-17 Gi Innovation Inc Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof
KR20220011931A (en) * 2020-07-22 2022-02-03 (주)지아이이노베이션 Fusion protein comprising ige fc receptor and use for treating canine allergic diseases comprising the same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH092959A (en) * 1995-06-16 1997-01-07 Yakult Honsha Co Ltd Immuno-globulin e antibody production suppressant and antiallergic agent
JPH10309178A (en) * 1997-05-09 1998-11-24 Wakamoto Pharmaceut Co Ltd Antiallergic agent and fermented food containing bifidus bacterium as active component
JP2000095697A (en) * 1998-09-18 2000-04-04 Advance Co Ltd Antiallergic agent
AUPQ415899A0 (en) * 1999-11-19 1999-12-16 Vasse Research Institute Pty Ltd Compositions for and methods of treatment of allergic diseases
EP1239032A1 (en) * 2001-03-02 2002-09-11 Société des Produits Nestlé S.A. Lactic acid bacteria as agents for treating and preventing allergy
JP2009067679A (en) * 2005-12-27 2009-04-02 Univ Of Tokushima Pharmaceutical having anti-histamine activity
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
WO2008071751A1 (en) * 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
AR065368A1 (en) * 2007-02-15 2009-06-03 Astrazeneca Ab ANTIBODIES FOR IGE MOLECULES
JP5577243B2 (en) * 2007-05-30 2014-08-20 ポステク アカデミー−インダストリー ファウンデイション Immunoglobulin fusion protein
EP2065048A1 (en) * 2007-11-30 2009-06-03 Institut Pasteur Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation
BRPI0908348A2 (en) * 2008-02-06 2015-07-28 Procter & Gamble Methods and kits of compositions for enhancing the immune response to a respiratory condition
WO2010013143A2 (en) * 2008-08-01 2010-02-04 Institut Pasteur Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillus
PL3190128T3 (en) 2008-09-17 2019-06-28 Xencor, Inc. Compositions and methods for treating ige-mediated disorders
RU2642295C2 (en) * 2009-10-26 2018-01-24 Дженентек, Инк. Analysis of identification of antibodies specific to therapeutic antibodies against ige, and their application in anaphylaxis
KR20120135865A (en) * 2011-06-07 2012-12-17 (주)네오팜 CONJUGATE COMPRISING SOLUBLE FRAGMENT OF FcεRI AND COMPOSITION FOR TREATING ALLERGY DISEASES MEDIATED BY IGE COMPRISING THE CONJUGATE
WO2012169735A2 (en) * 2011-06-07 2012-12-13 (주)네오팜 Complex comprising water-soluble fragments of fcεri and composition comprising same for treating allergic diseases mediated by ige
CN103169733B (en) * 2011-12-26 2014-11-12 浙江贝因美科工贸股份有限公司 Compound probiotic, application thereof for treating anaphylactic diseases and allergy free probiotic electuary for pregnant and lying-in women
TWI691512B (en) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Fc fusion high affinity IgE receptor alpha chain
CN107949393A (en) * 2015-03-12 2018-04-20 不列颠哥伦比亚大学 Bacteria composition and its application process
KR101778734B1 (en) 2016-03-11 2017-09-18 대한민국(농촌진흥청장) Extracellular Solute Binding Protein (ESBP) derived from Bifidobacterium longum KACC 91563 and Anti-allergy Composition using the Same
SG11202005858WA (en) * 2018-01-08 2020-07-29 Gi Innovation Inc Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same

Also Published As

Publication number Publication date
US20220347236A1 (en) 2022-11-03
CN111587118A (en) 2020-08-25
PE20210108A1 (en) 2021-01-19
IL275593B (en) 2022-01-01
EP3738599C0 (en) 2023-12-27
JP7041272B2 (en) 2022-03-23
KR20190086396A (en) 2019-07-22
AU2019206205A1 (en) 2020-06-25
KR102038679B1 (en) 2019-10-30
IL275593A (en) 2020-08-31
PH12020551069A1 (en) 2021-09-06
EP3738599B1 (en) 2023-12-27
EP3738599A4 (en) 2021-10-27
MX2020007032A (en) 2020-12-03
RU2020122021A (en) 2022-02-14
TW201932129A (en) 2019-08-16
CA3086224A1 (en) 2019-07-18
WO2019139434A1 (en) 2019-07-18
EP3738599A1 (en) 2020-11-18
CL2020001800A1 (en) 2020-10-30
BR112020013818A2 (en) 2020-12-01
JP2021510689A (en) 2021-04-30
TWI737955B (en) 2021-09-01
CN111587118B (en) 2023-11-21

Similar Documents

Publication Publication Date Title
IL281783A (en) Sirpα binding proteins and methods of use thereof
GB2613715B (en) Binding proteins specific for RAS neoantigens and uses thereof
ZA202003788B (en) Composition based on probiotics and uses thereof
IL265489B (en) Recombinant binding proteins and their use
IL275593B (en) Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
IL284633A (en) Polypeptides comprising modified il-2 polypeptides and uses thereof
IL279201A (en) Multi-specific binding proteins and methods of use thereof
IL287781A (en) Clec12a-binding polypeptides and uses thereof
IL284381A (en) Activatable masked anti-clta4 binding proteins, compositions comprising the same and uses thereof
IL288610A (en) Recombinant fap binding proteins and their use
EP3705121A4 (en) Emopamil binding protein binding agent and use thereof
IL287782A (en) Cd33-binding polypeptides and uses thereof
EP3445394A4 (en) Alk7 binding proteins and uses thereof
IL280808A (en) Ox40-binding polypeptides and uses thereof
ZA202100092B (en) Modified cas9 protein and use thereof
GB201819200D0 (en) Polypeptide and uses thereof
EP4063489A4 (en) Composition and use thereof
IL270949A (en) Protease and binding polypeptide for o-glycoproteins
EP3816186A4 (en) Pd-l1-binding polypeptide and use thereof
GB2603645B (en) Polypeptides having anti-senescent effects and uses thereof
GB202201001D0 (en) Polypeptide and use thereof
EP3700571A4 (en) Alk7 binding proteins and uses thereof
GB201819850D0 (en) Polypeptide and its use in affinity purification
EP3976656A4 (en) Alk7 binding proteins and uses thereof
EP3976630A4 (en) Actrii-binding proteins and uses thereof